Results 151 to 160 of about 2,341,500 (267)

Adaptive Spo11 RNA editing gate optimizes meiosis I pace and mitotic proliferation while preserving ascospore formation. [PDF]

Sci Adv
Wu M, Liu J, Han J, Huang J, Feng C, Jiang C, Xu JR, Wang Q, Liu H.   +8 more
europepmc   +1 more source

Targeting transcription factors associated with hemoglobinopathies: Lessons from successful interventions and implications for cancer

Molecular Oncology, EarlyView.
This review summarizes the transcription factors, repressive chromatin‐modifying complexes, and epigenetic mechanisms that control fetal hemoglobin repression. Notably, many regulators of γ‐globin silencing also function in transcriptional and epigenetic networks that drive cancer, highlighting opportunities to translate advances in hemoglobinopathy ...
Meigen Yu, Puspa Das, Xing Zhang, Xiaodong Cheng   +3 more
wiley   +1 more source

Site-specific neoepitope induction by RNA editing reprograms tumor immunogenicity. [PDF]

Front Immunol
Liu S, Dong C, Chen L, Yan J, Luo X, Huang H, Qiu Z, Gan X, Yang J, Zhu J, Xiong C, Huang L, Wang L, Yang Z, Meng Z, Yi S, Chen Y, Zuo C, Leng Q, Wang X.   +19 more
europepmc   +1 more source

Interferon beta drives therapy resistance in a patient‐derived model of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Interferon type 1 (IFN‐1) production and signaling is associated with the acquisition of therapy resistance, following chronic DNA damage, via Interferon‐related DNA damage resistance signature (IRDS) gene expression. An alternative, DNA damage‐independent role of sustained IFN‐1 mediated resistance was identified and characterized by the emergence of ...
Ashlyn Conant, Tise Suzuki, Kiera McGivney, V. S. S. Abhinav Ayyadevara, Sharon Asariah, Jay Deng, Ethan Nyein, Jacqueline Coats, Gary Yu, Yevgeniya J. Ioffe, Christian Hurtz, Juli J. Unternaehrer   +11 more
wiley   +1 more source

On the Label: Implementation of Health Warnings on Alcohol Products in 13 European Countries. [PDF]

Drug Alcohol Rev
Kokole D, Neufeld M, Correia D, Rehm J, Pettigrew S, Paradis C, Borges CF, Fernández-Shaw AN, Pinho AP, Pereira C, Juškevičiūtė E, Savvidou E, de Veld J, Plešnar L, Mergaert L, Bermúdez LC, Sawaya M, Šelović M, Kiguolytė M, Patalong M, Senica P, Palacio PL, Mitra S, Suarez Tostado S.   +23 more
europepmc   +1 more source

CEACAM1 participation in breast cancer progression

Molecular Oncology, EarlyView.
In invasive breast cancer (BC), CEACAM1 shifts from an apical to a uniform membranous/cytoplasmic pattern, or is lost, as tumors dedifferentiate, inversely tracking the Ki‐67 proliferative index. In MCF‐7 cells, only CEACAM1‐4L suppresses proliferation, repressing cell cycle and growth factor genes.
Mykola Lyndin, Irina Kube‐Golovin, Anatolii Romaniuk, Gunther Wennemuth   +3 more
wiley   +1 more source

ADA2 genotype and enzyme activity may predict vasculitic or hematologic DADA2 phenotype. [PDF]

J Hum Immun
Peters P, Schepp J, Albert MH, von Bernuth H, Blank N, Brunner J, Dückers G, Ehlers L, Farmand S, Föll D, Förster-Waldl E, Gburek-Augustat J, Ghosh S, Göschl L, Hömberg M, Hönig M, Kallinich T, Klemann C, Klingel L, Kontny U, Kuhn LM, Lamprecht P, Lehmberg K, Meyer-Bahlburg A, Müller I, Nathrath M, Niehues T, Oommen PT, Pachlopnik Schmid J, Prader S, Puzik A, Renella R, Schulz A, Skrabl-Baumgartner A, Starke S, Tarrant TK, Hershfield M, Grimbacher B, Hauck F.   +38 more
europepmc   +1 more source

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

Molecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas, Barbara Karakyriakou, Patricia C. Muskus, Alyssa M. Roberts, Justin Rendleman, Alexa Warren, Hanxu Lu, Kimberly A. Birmingham, Malone K. Friedman, Abigail E. Goen, Huijuan Yang, Owen M. Wilkins, Fred W. Kolling, Eugene Demidenko, Julie M. Jorns, Brock C. Christensen, Todd W. Miller   +16 more
wiley   +1 more source

Publishing as knowledge clubs: ASSAf Statement on the Recognition of Editors and Peer Reviewers

South African Journal of Science
Keyan G. Tomaselli
doaj   +1 more source

PANoptosis in the pathogenesis of myelodysplastic syndromes

Molecular Oncology, EarlyView.
PANoptosis, a combination of three types of programmed cell death, is mediated by a large protein complex called a PANoptosome. In healthy bone marrow hematopoietic cells, PANoptosis is restricted by inhibitory signaling. In MDS, bone marrow cells become sensitive to the PANoptotic stimuli due to the aberrant inactivation of inhibitory signaling or ...
Rohit Thalla, Jyoti Lamichhane, Cameron Lewis, Peter Breslin, Jiwang Zhang   +4 more
wiley   +1 more source